The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Announcing the first novel class of rapid-onset antidepressants in clinical practice
Open accessAbstract
This study was designed with the rational aim/purpose of announcing and discussing the new class of rapid-onset antidepressants that will bring forth significant improvement and positive impact to the management of patients with depression disorders in clinical practice. The class of N-methyl-D-aspartate-glutamatergic ionoceptor blockers represent the first separate novel class of rapid-onset antidepressants with a direct action on the excitatory glutamatergic neurotransmission system but no direct action on the serotonergic, noradrenergic, or dopaminergic neurotransmission systems. It consistently fits into the antidepressants' classification nomenclature, and the pharmacological properties also deemed it appropriate to be accepted and announced as the first separate novel class of rapid-onset antidepressants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Developed for adjunctive use for TRD, apimostinel acts as a functional antagonist at the glycine B site of NMDA receptors [165].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [165]
In the citing paper
“Apimostinel (NRX-1074/AGN-241751) is a higher-potency rapastinel analog with increased bioavailability.”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [165]
In the citing paper
“Apimostinel has been tested in two phase I studies and a larger phase II RDBPCT, showing rapid AD effects after a single, high-dose IV administration [165].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [165]
Citations
Cites
Automated electron microscope tomography using robust prediction of specimen movements
Mastronarde, D. N. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.07.007 · Cited by 5,336
SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information
Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Cassarino, T. G., Bertoni, M., Bordoli, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku340 · Cited by 4,632
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139
Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Molecular cloning and characterization of the rat NMDA receptor
Moriyoshi, K., Masu, M., Ishii, T., Shigemoto, R., Mizuno, N., & Nakanishi, S. (1991) · Nature · doi:10.1038/354031a0 · Cited by 1,771
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Accurate determination of local defocus and specimen tilt in electron microscopy
Mindell, J. A., & Grigorieff, N. (2003) · Journal of Structural Biology · doi:10.1016/s1047-8477(03)00069-8 · Cited by 1,407
Subunit arrangement and function in NMDA receptors
Furukawa, H., Singh, S. K., Mancusso, R., & Gouaux, E. (2005) · Nature · doi:10.1038/nature04089 · Cited by 786
Crystal structure of a heterotetrameric NMDA receptor ion channel
Karakas, E., & Furukawa, H. (2014) · Science · doi:10.1126/science.1251915 · Cited by 603
Single-Particle Cryo-EM at Crystallographic Resolution
Cheng, Y. (2015) · Cell · doi:10.1016/j.cell.2015.03.049 · Cited by 581
Auer, D. P., Pütz, B., Kraft, E., Lipinski, B., Schill, J., & Holsboer, F. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00159-6 · Cited by 564
NMDA receptor structures reveal subunit arrangement and pore architecture
Lee, C.-H., Lü, W., Michel, J. C., Goehring, A., Du, J., Song, X., & Gouaux, E. (2014) · Nature · doi:10.1038/nature13548 · Cited by 520
Furukawa, H. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg303 · Cited by 507 · cited 1×
“Currently, the NMDAR is a heteromeric complex that has three (3) different subunits with a total of fourteen (14) isoform variants for all of these subunits.”
BackgroundEndele, S., Rosenberger, G., Geider, K., Popp, B., Tamer, C., Stefanova, I., Milh, M., Kortüm, F., Fritsch, A., Pientka, F. K., et al. (2010) · Nature Genetics · doi:10.1038/ng.677 · Cited by 499
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480
Fischer, G., Mutel, V., Trube, G., Malherbe, P., Kew, J. N. C., Mohacsi, E., Heitz, M. P., & Kemp, J. A. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37138-1 · Cited by 479
EVANS, R. H., FRANCIS, A. A., JONES, A. W., SMITH, D. A. S., & WATKINS, J. C. (1982) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1982.tb08758.x · Cited by 467
Lesca, G., Rudolf, G., Bruneau, N., Lozovaya, N., Labalme, A., Boutry-Kryza, N., Salmi, M., Tsintsadze, T., Addis, L., Motte, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2726 · Cited by 439
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors
Karakas, E., Simorowski, N., & Furukawa, H. (2011) · Nature · doi:10.1038/nature10180 · Cited by 341
Mechanism of differential control of NMDA receptor activity by NR2 subunits
Gielen, M., Retchless, B. S., Mony, L., Johnson, J. W., & Paoletti, P. (2009) · Nature · doi:10.1038/nature07993 · Cited by 325
An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
Zarate, C. A., Payne, J. L., Quiroz, J., Sporn, J., Denicoff, K. K., Luckenbaugh, D., Charney, D. S., & Manji, H. K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.171 · Cited by 324
Subunit- and site-specific pharmacology of the NMDA receptor channel
Yamakura, T., & Shimoji, K. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00007-6 · Cited by 311
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.105 · Cited by 271
Beneyto, M., & Meador-Woodruff, J. H. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301604 · Cited by 259
Zarate, C. A., Mathews, D., Ibrahim, L., Chaves, J. F., Marquardt, C., Ukoh, I., Jolkovsky, L., Brutsche, N. E., Smith, M. A., & Luckenbaugh, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.019 · Cited by 255
Direct Conversion of EPR Dipolar Time Evolution Data to Distance Distributions
Jeschke, G., Koch, A., Jonas, U., & Godt, A. (2002) · Journal of Magnetic Resonance · doi:10.1006/jmre.2001.2498 · Cited by 241
Kew, J. N., Trube, G., & Kemp, J. A. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021807 · Cited by 240
Sanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236
Mchaourab, H. S., Steed, P. R., & Kazmier, K. (2011) · Structure · doi:10.1016/j.str.2011.10.009 · Cited by 234
Structural mechanism of glutamate receptor activation and desensitization
Meyerson, J. R., Kumar, J., Chittori, S., Rao, P., Pierson, J., Bartesaghi, A., Mayer, M. L., & Subramaniam, S. (2014) · Nature · doi:10.1038/nature13603 · Cited by 226
Armstrong, N., Jasti, J., Beich-Frandsen, M., & Gouaux, E. (2006) · Cell · doi:10.1016/j.cell.2006.08.037 · Cited by 220 · cited 1×
“The glutamate system has an integrated tripartite synapse that consists of: (1) a presynaptic neuron, (2) a postsynaptic neuron, and (3) an astrocyte.”
BackgroundStructure and Dynamics of AMPA Receptor GluA2 in Resting, Pre-Open, and Desensitized States
Dürr, K. L., Chen, L., Stein, R. A., De Zorzi, R., Folea, I. M., Walz, T., Mchaourab, H. S., & Gouaux, E. (2014) · Cell · doi:10.1016/j.cell.2014.07.023 · Cited by 201
Structure of the zinc‐bound amino‐terminal domain of the NMDA receptor NR2B subunit
Karakas, E., Simorowski, N., & Furukawa, H. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.338 · Cited by 201
Sanacora, G., Kendell, S. F., Levin, Y., Simen, A. A., Fenton, L. R., Coric, V., & Krystal, J. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.037 · Cited by 199
Neuroenergetics and the kinetic design of excitatory synapses
Attwell, D., & Gibb, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1784 · Cited by 191 · cited 2×
“According to the studies carried out by Das and colleagues in 1998 demonstrating the existence of these two (2) varieties of the NR3 subunits (NR3A and NR3B), which are coded by different genes.”
BackgroundDifferent sensitivities of NMDA receptor channel subtypes to non-competitive antagonists
Yamakura, T., Mori, H., Masaki, H., Shimoji, K., & Mishina, M. (1993) · NeuroReport · doi:10.1097/00001756-199306000-00021 · Cited by 181
Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes
Azbill, R. D., Mu, X., & Springer, J. E. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02430-6 · Cited by 175
Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines
Mony, L., Zhu, S., Carvalho, S., & Paoletti, P. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.203 · Cited by 170
Ghasemi, M., Kazemi, M., Yoosefi, A., Ghasemi, A., Paragomi, P., Amini, H., & Afzali, M. H. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.12.008 · Cited by 161
Lara, D. R., Bisol, L. W., & Munari, L. R. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000485 · Cited by 152
NMDAR-independent, cAMP-dependent antidepressant actions of ketamine
Wray, N. H., Schappi, J. M., Singh, H., Senese, N. B., & Rasenick, M. M. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0083-8 · Cited by 133
Structural Rearrangements of NR1/NR2A NMDA Receptors during Allosteric Inhibition
Gielen, M. C., Goff, A. L., Stroebel, D., Johnson, J. W., Neyton, J., & Paoletti, P. (2008) · Neuron · doi:10.1016/j.neuron.2007.11.021 · Cited by 130
Structural Insights into Competitive Antagonism in NMDA Receptors
Jespersen, A., Tajima, N., Fernández‐Cuervo, G., Garnier‐Amblard, E. C., & Furukawa, H. (2014) · Neuron · doi:10.1016/j.neuron.2013.11.033 · Cited by 92
Emerging Models of Glutamate Receptor Ion Channel Structure and Function
Mayer, M. L. (2011) · Structure · doi:10.1016/j.str.2011.08.009 · Cited by 92
Baron, B. M., Siegel, B. W., Slone, A. L., Harrison, B. L., Palfreyman, M. G., & Hurt, S. D. (1991) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(91)90023-b · Cited by 66
Stability of ligand‐binding domain dimer assembly controls kainate receptor desensitization
Chaudhry, C., Weston, M. C., Schuck, P., Rosenmund, C., & Mayer, M. L. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.86 · Cited by 64 · cited 1×
“com J Med Sci 2019;39 (5):205‐216 DOI:10.”
Monoamine depletion in unmedicated depressed subjects.
Berman, R., Sanacora, G., Anand, A., Roach, L. M., Fasula, M. K., Finkelstein, C., Wachen, R., Oren, D., Heninger, G., & Charney, D. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01285-9 · Cited by 53
Kinetics of NMDA Channel Opening
Dzubay, J. A., & Jahr, C. E. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-13-04129.1996 · Cited by 50
Zigman, D., & Blier, P. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182856865 · Cited by 27
Cheriyan, J., Mezes, C. M., Zhou, N., Balsara, R. D., & Castellino, F. (2014) · Biochemistry · doi:10.1021/bi501437s · Cited by 7
Cited by
Encore: Behavioural animal models of stress, depression and mood disorders
Petković, A., & Chaudhury, D. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.931964 · Cited by 85
“In previous decades, there has not been much progress in the discovery of completely novel non-monoaminergic antidepressants, with exception of NMDA-receptor blockers, such as ketamine (Zanos and Gould, 2018; Fasipe, 2019; Fasipe et al., 2019).”
BackgroundPharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Apimostinel has been tested in two phase I studies and a larger phase II RDBPCT, showing rapid AD effects after a single, high-dose IV administration [165].”
BackgroundGlutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets
Panek, M., Kawalec, P., Malinowska‐Lipień, I., Brzostek, T., & Pilc, A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1836160 · Cited by 17
Fasipe, O. J., Agede, O. A., & Enikuomehin, A. C. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0108 · Cited by 18
Self-citationShnayder, N. A., Kidyaeva, A. V., Vaiman, E. E., Asadullin, A. R., Петрова, М. М., Kaskaeva, D. S., Matyushin, G. V., Evsyukov, A. A., Galko, E. V., Garganeeva, N. P., et al. (2023) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2023-3-2-72-119 · Cited by 11
“This class of ADs includes bupropion [62, 63].”
BackgroundInfluential
Metadata
- Authors
- Fasipe, O., Akhideno, P., Owhin, O., & Ibiyemi-Fasipe, O.
- Affiliations
- Irrua Specialist Teaching Hospital (NG)
- Venue
- Journal of Medical Sciences
- Published
- 2019
- Volume
- 39
- Issue
- 5
- Pages
- 205
- ISSN
- 1011-4564 (ISSN-L)
- OpenAlex
- W2978832855
- Cited by
- 6
- References
- 59
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 1 · 2020: 2
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Medical Sciences (publishedVersion, cc-by-nc-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- rapid-acting antidepressants, NMDA receptor antagonists, glutamatergic neurotransmission, depression, antidepressant classification, clinical practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.